HIV/AIDS and Mental Health: Depression, Stigma, Neurocognitive Effects, Antiretroviral Psychiatric Side Effects, and Integrated Care Models

Human Immunodeficiency Virus (HIV) infection and its progression to Acquired Immunodeficiency Syndrome (AIDS) represent far more than an immunological disease. Since the earliest years of the epidemic, clinicians have recognized that HIV exerts profound effects on the central nervous system (CNS) and that people living with HIV (PLWH) experience psychiatric disorders at rates substantially exceeding the general population. Mental health comorbidity in HIV is not ancillary — it is a primary driver of disease progression, antiretroviral therapy (ART) non-adherence, viral non-suppression, and mortality.

Globally, approximately 39 million people were living with HIV at the end of 2023 (UNAIDS estimates). Among this population, major depressive disorder (MDD) occurs at roughly 2–3 times the general population rate, with meta-analytic prevalence estimates ranging from 20–40% depending on diagnostic method and population studied. Anxiety disorders, substance use disorders, post-traumatic stress disorder (PTSD), and HIV-associated neurocognitive disorder (HAND) further compound the clinical picture. The interaction between these psychiatric conditions and HIV creates bidirectional pathophysiology: depression accelerates immune decline, while HIV neuropathology produces psychiatric symptoms that mimic or exacerbate primary mental disorders.

This article examines the neurobiology, epidemiology, diagnosis, treatment, and service delivery models relevant to psychiatric care in HIV/AIDS. It moves beyond surface-level awareness to engage with the specific mechanisms, outcome data, and clinical controversies that inform evidence-based practice for this population.

The epidemiological burden of psychiatric illness in PLWH is staggering and well-documented across multiple large-scale studies and meta-analyses.

Depression

A landmark meta-analysis by Ciesla and Roberts (2001), covering 10 studies and over 2,500 participants, found that PLWH were nearly twice as likely to meet criteria for MDD compared to HIV-negative controls (OR = 1.99, 95% CI: 1.32–3.00). More recent meta-analyses have refined this estimate. Nakimuli-Mpungu et al. (2012) reported pooled depression prevalence of 31.2% across sub-Saharan African HIV cohorts. A 2019 systematic review by Rezaei et al. estimated global pooled prevalence of depressive symptoms at 39.1% using self-report measures and 22.2% using structured diagnostic interviews — highlighting the critical distinction between screening-tool prevalence and diagnostic prevalence.

Anxiety Disorders

Generalized anxiety disorder (GAD), panic disorder, and social anxiety disorder are elevated in PLWH, with prevalence estimates ranging from 15–25%. PTSD prevalence is particularly notable, estimated at 15–30% in PLWH populations — roughly 3–5 times the general population rate of approximately 6–7% (DSM-5-TR lifetime prevalence). This elevation reflects the high rates of prior trauma exposure, including sexual violence, childhood abuse, and the traumatic nature of an HIV diagnosis itself.

Substance Use Disorders

Co-occurring substance use disorders (SUDs) affect an estimated 40–60% of PLWH in U.S.-based clinical cohorts. The HIV Cost and Services Utilization Study (HCSUS), a nationally representative U.S. sample, found that 50% of PLWH screened positive for a mental health or substance use condition, with drug dependence present in approximately 12% and hazardous alcohol use in approximately 20%.

Suicidality

PLWH have substantially elevated suicide risk. A meta-analysis by Catalan et al. (2011) estimated a suicide rate approximately 2–3 times that of the general population, with higher rates in the period immediately following diagnosis. In the pre-ART era, relative risk of suicide was even higher (estimated RR = 7–36 in early studies), though this has decreased with improvements in prognosis.

HIV-Associated Neurocognitive Disorder (HAND)

Despite the success of combination ART in reducing AIDS-defining illness, HAND remains prevalent. The landmark CHARTER study (CNS HIV Antiretroviral Therapy Effects Research), involving over 1,500 PLWH in the U.S., found that approximately 52% of participants met criteria for HAND: 33% with asymptomatic neurocognitive impairment (ANI), 12% with mild neurocognitive disorder (MND), and 2% with HIV-associated dementia (HAD). While HAD has declined dramatically in the ART era — from approximately 15–20% of AIDS patients pre-ART to 2–5% currently — milder forms of HAND have remained stubbornly prevalent.

HIV is neurotropic — the virus enters the CNS within days of initial infection and establishes a reservoir that persists even when peripheral viral load is undetectable on ART. Understanding the specific neurobiological mechanisms by which HIV produces psychiatric and cognitive symptoms is essential for differential diagnosis and treatment planning.

Viral Entry and Neuroimmune Activation

HIV does not infect neurons directly. Instead, it enters the CNS via a "Trojan horse" mechanism, crossing the blood-brain barrier (BBB) inside infected monocytes and CD4+ T-lymphocytes. Once in the CNS, the virus productively infects microglia and perivascular macrophages. These infected cells release viral proteins — particularly gp120 (envelope glycoprotein) and Tat (transactivator of transcription) — that are directly neurotoxic. Additionally, infected and activated microglia produce a cascade of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and quinolinic acid, a neurotoxic metabolite of the kynurenine pathway.

The Kynurenine Pathway and Serotonergic Dysfunction

The kynurenine pathway is a critical link between HIV-driven neuroinflammation and depression. Under inflammatory conditions, the enzyme indoleamine 2,3-dioxygenase (IDO) is upregulated, diverting tryptophan metabolism away from serotonin synthesis and toward kynurenine production. This has a dual pathological effect: (1) serotonin depletion, contributing to depressive symptoms through reduced 5-HT availability in prefrontal and limbic circuits, and (2) accumulation of quinolinic acid, an NMDA receptor agonist that produces excitotoxic neuronal damage, particularly in the hippocampus and basal ganglia. Elevated cerebrospinal fluid (CSF) quinolinic acid levels have been correlated with both neurocognitive impairment and depressive severity in PLWH in multiple studies.

Dopaminergic Circuit Disruption

HIV shows particular tropism for basal ganglia structures — the caudate nucleus, putamen, and globus pallidus — and the substantia nigra. Neuropathological studies consistently demonstrate dopaminergic neuronal loss and reduced dopamine transporter (DAT) density in PLWH. Viral protein Tat directly inhibits DAT function, increasing synaptic dopamine acutely but leading to dopaminergic neurotoxicity chronically. This basal ganglia pathology underlies several features of HAND: psychomotor slowing, executive dysfunction, apathy, and procedural learning deficits — a profile historically described as a "subcortical dementia" pattern. The dopaminergic disruption also has direct relevance to anhedonia, motivational deficits, and the overlap between HAND-related apathy and MDD.

Hippocampal and Prefrontal Cortex Pathology

Neuroimaging studies in PLWH consistently demonstrate volume loss in the hippocampus, prefrontal cortex, and anterior cingulate cortex — regions central to mood regulation, episodic memory, and executive function. Functional MRI studies reveal altered resting-state connectivity in the default mode network and fronto-striatal circuits. These structural and functional changes are correlated with both depressive severity and neurocognitive performance, supporting a shared neuroanatomical substrate for mood and cognitive symptoms in HIV.

HPA Axis Dysregulation

Chronic HIV infection is associated with hypothalamic-pituitary-adrenal (HPA) axis abnormalities, including elevated basal cortisol and blunted diurnal cortisol rhythmicity. This mirrors the HPA axis dysregulation seen in MDD and is thought to contribute to hippocampal neurodegeneration, immune dysregulation, and metabolic complications. The interaction between HIV-related immune activation and HPA axis dysfunction creates a self-reinforcing cycle of inflammation, cortisol excess, and neuropsychiatric decline.

Genetic Vulnerability

Host genetic factors modulate psychiatric risk in HIV. Polymorphisms in the serotonin transporter gene (SLC6A4), particularly the short allele of the 5-HTTLPR promoter region, have been associated with increased depression risk in PLWH. Variations in genes encoding inflammatory mediators (e.g., TNF-α, IL-6) and the apolipoprotein E ε4 allele (APOE ε4) — well-established in Alzheimer's disease research — have been implicated in accelerated neurocognitive decline in HIV, though findings remain inconsistent and require replication.

Accurate psychiatric diagnosis in PLWH is complicated by substantial symptom overlap between primary psychiatric disorders, HIV-related CNS disease, ART side effects, opportunistic infections, and systemic illness. Failure to navigate these differentials leads to misdiagnosis, inappropriate treatment, and missed reversible etiologies.

Depression vs. HAND-Related Apathy

Distinguishing MDD from the apathetic syndrome associated with HAND is a common and consequential clinical challenge. Both conditions present with psychomotor retardation, diminished interest, poor concentration, and functional decline. Key differentiating features include:

• Sadness, guilt, and worthlessness — characteristic of MDD but typically absent in HAND-related apathy
• Prominent executive dysfunction and psychomotor slowing disproportionate to mood disturbance — suggestive of HAND
• Neuropsychological testing profile — HAND produces a subcortical pattern (processing speed, motor function, learning efficiency deficits), while primary MDD is more associated with effortful processing deficits without the characteristic motor slowing
• Response to antidepressant treatment — pure HAND-related apathy does not improve with SSRIs and may respond better to dopaminergic agents

Somatic Symptom Overlap

The DSM-5-TR criteria for MDD include somatic symptoms — fatigue, insomnia, appetite changes, weight loss, and psychomotor retardation — that are also direct consequences of HIV disease, opportunistic infections, and ART toxicity. Using these somatic symptoms uncritically to diagnose depression in advanced HIV disease inflates diagnostic sensitivity at the cost of specificity. The Endicott substitution criteria replace somatic items with cognitive/affective alternatives (e.g., substituting "social withdrawal" for "fatigue") and have been validated in medically ill populations including HIV, though they are not universally adopted in clinical practice.

Mania and HIV

New-onset mania in PLWH, particularly late in disease course with advanced immunosuppression (CD4 < 200 cells/μL), raises the possibility of secondary mania — a syndrome caused by direct CNS HIV effects, opportunistic CNS infection (e.g., toxoplasmosis, progressive multifocal leukoencephalopathy, CMV encephalitis), or CNS lymphoma. Secondary mania differs from primary bipolar disorder in several respects: it tends to occur at an older age, lacks a family history of mood disorders, and is often accompanied by cognitive impairment and neurological signs. Neuroimaging and lumbar puncture are indicated when new-onset mania occurs in the context of advanced HIV disease.

Delirium

Delirium is common in hospitalized PLWH, particularly those with advanced immunosuppression, and must be distinguished from psychotic features of primary psychiatric disorders. Waxing-and-waning consciousness, inattention, and acute onset are hallmarks. Etiologies include opportunistic infections (cryptococcal meningitis, toxoplasmosis, CMV encephalitis), metabolic derangements, medication effects, and substance intoxication/withdrawal.

Screening Recommendations

U.S. Department of Health and Human Services (DHHS) HIV treatment guidelines recommend routine mental health screening at HIV diagnosis and periodically thereafter. The PHQ-9 (Patient Health Questionnaire-9) is widely used for depression screening and has been validated in PLWH across diverse settings. A cutoff of ≥10 provides reasonable sensitivity (approximately 83–92%) and specificity (approximately 72–85%) for MDD in HIV populations, though some studies suggest a higher cutoff of ≥12 may improve specificity in this medically complex population.

Despite the high prevalence and well-documented adverse impact of depression on HIV outcomes, treatment data in PLWH are less robust than for the general population, and treatment gaps remain wide — an estimated 50–75% of depressed PLWH do not receive adequate mental health treatment.

Pharmacotherapy

Selective serotonin reuptake inhibitors (SSRIs) are considered first-line pharmacotherapy for depression in PLWH, supported by multiple randomized controlled trials (RCTs). A Cochrane systematic review by Himelhoch et al. (2005, updated subsequently) identified modest but statistically significant benefits of antidepressants over placebo in PLWH, with effect sizes comparable to those seen in general MDD populations (standardized mean difference approximately 0.57 for imipramine, approximately 0.33 for fluoxetine). Specific findings include:

• Fluoxetine — the most studied SSRI in HIV populations. An RCT by Zisook et al. (1998) demonstrated superiority over placebo with response rates of approximately 56% vs. 38%.
• Sertraline — generally well-tolerated with fewer drug-drug interactions than some other SSRIs. Has relatively modest CYP450 inhibition.
• Escitalopram and citalopram — favored for their minimal CYP450 interaction profile, reducing the risk of clinically significant drug-drug interactions with ART.
• Paroxetine — effective but a potent CYP2D6 inhibitor, creating interaction risk with protease inhibitors and other ART agents. Generally not preferred.

Drug-drug interactions are a paramount concern when prescribing psychiatric medications alongside ART. Protease inhibitors (PIs) such as ritonavir and cobicistat are potent inhibitors of CYP3A4, and some are inhibitors or inducers of CYP2D6 and other isoenzymes. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as efavirenz are CYP3A4 inducers. These interactions can significantly alter psychiatric medication levels:

• Ritonavir may increase levels of tricyclic antidepressants (TCAs), trazodone, and some benzodiazepines (alprazolam, midazolam — the latter is contraindicated) by inhibiting CYP3A4 metabolism.
• Efavirenz may decrease levels of methadone and some antidepressants metabolized via CYP3A4, potentially precipitating treatment failure or opioid withdrawal.
• St. John's Wort is strictly contraindicated with all ART classes due to CYP3A4 induction, which can reduce ART levels to subtherapeutic concentrations and promote viral resistance.

Clinicians should routinely consult drug interaction databases (e.g., the Liverpool HIV Drug Interaction Checker) before prescribing psychotropic agents to PLWH.

Psychotherapy

Cognitive-behavioral therapy (CBT) and interpersonal therapy (IPT) have the strongest evidence base for depression treatment in PLWH. A meta-analysis by Sherr et al. (2011) found moderate effect sizes for psychological interventions in reducing depressive symptoms in PLWH (pooled Cohen's d ≈ 0.51). Specific evidence includes:

• CBT — multiple RCTs demonstrate efficacy, with response rates of approximately 50–65% in HIV-specific adaptations. CBT-AD (CBT for Adherence and Depression), developed by Safren et al., is a notable integrated intervention that simultaneously targets depressive symptoms and ART adherence, with RCTs demonstrating improvements in both outcomes.
• IPT — effective across diverse HIV populations, including in sub-Saharan Africa. Bolton et al. (2003) demonstrated significant depression reduction in a group IPT trial in Uganda among individuals with HIV and depression.
• Behavioral activation — emerging evidence supports feasibility and efficacy in PLWH, with particular relevance to the anhedonia and activity withdrawal common in this population.

Combined Treatment

As in general MDD treatment, combined pharmacotherapy and psychotherapy is likely superior to either alone for moderate-to-severe depression, though head-to-head comparisons specifically in PLWH are limited. The collaborative care model (stepped care with measurement-based treatment) has shown particular promise in HIV clinic settings.

Treatment Effect on HIV Outcomes

Critically, depression treatment in PLWH improves not only mood but also ART adherence, viral suppression, and possibly immunological outcomes. A meta-analysis by Sin and DiMatteo (2014) found that depressed medical patients have 1.76 times the odds of medication non-adherence, and depression treatment consistently improves adherence metrics. The NIMH-funded Strategies for Management of Antiretroviral Therapy (SMART) study and other cohort data suggest that sustained viral suppression is significantly less likely in the presence of untreated depression.

HIV-related stigma is not merely a psychosocial stressor — it is a fundamental structural determinant of mental health outcomes, treatment engagement, and survival in PLWH. Erving Goffman's foundational conceptualization of stigma as a "spoiled identity" remains relevant, but the field has progressed to identify specific dimensions and mechanisms through which HIV stigma exerts its pathological effects.

Dimensions of HIV Stigma

Contemporary models distinguish several forms of stigma:

• Enacted stigma — direct experiences of discrimination, rejection, or violence due to HIV status. This includes employment discrimination, social exclusion, healthcare discrimination, and intimate partner violence.
• Anticipated stigma — the expectation that one will experience discrimination if HIV status is disclosed. This drives concealment behavior and avoidance of healthcare settings.
• Internalized stigma — the endorsement of negative societal beliefs about PLWH and their application to oneself. This manifests as shame, self-blame, feelings of contamination, and diminished self-worth.
• Intersectional stigma — the convergence of HIV stigma with other marginalized identities, including sexual orientation, race, gender identity, injection drug use, and sex work. Intersectional stigma creates multiplicative, not merely additive, effects on mental health.

Quantification and Impact

The People Living with HIV (PLHIV) Stigma Index, conducted in over 100 countries, provides the most comprehensive global data on stigma experiences. Key findings from the Stigma Index 2.0 include: approximately 20% of PLWH report having been denied health services due to their HIV status; approximately 30% report avoiding healthcare due to anticipated stigma; and approximately 50% report internalized shame related to their HIV status.

Internalized HIV stigma is robustly associated with depressive symptoms, with correlations ranging from r = 0.40–0.60 across studies. A meta-analysis by Rueda et al. (2016) involving 64 studies and over 26,000 participants found that HIV stigma was significantly associated with greater depression severity (pooled OR = 1.93 for stigma-depression association), lower ART adherence, reduced access to care, and poorer quality of life. The effect sizes were substantial and consistent across geographic regions and study designs.

Neurobiological Pathways

Chronic stigma-related stress activates the same neuroendocrine and inflammatory pathways implicated in stress-related psychopathology. Repeated social threat and rejection activate the HPA axis and sympathetic nervous system, elevating cortisol and pro-inflammatory cytokines. In PLWH, this stigma-driven inflammation may synergize with HIV-related immune activation, compounding the neuroinflammatory burden on the CNS and accelerating both psychiatric and neurocognitive decline.

Stigma Reduction Interventions

Interventions targeting internalized stigma include cognitive-behavioral approaches, acceptance and commitment therapy (ACT), and group-based psychoeducation. The HIV Stigma Reduction Framework (Stangl et al., 2019) provides a systematic model for intervening at individual, community, and structural levels. However, evidence for sustained stigma reduction from individual-level interventions alone remains modest, and structural interventions (anti-discrimination legislation, healthcare worker training, community-level campaigns) are likely essential for durable change.

HAND represents a spectrum of neurocognitive impairment caused by HIV neuropathology, ranging from subclinical deficits to frank dementia. The Frascati criteria (Antinori et al., 2007), established by an international working group, define three severity levels:

• Asymptomatic Neurocognitive Impairment (ANI) — performance ≥1 SD below normative means in ≥2 cognitive domains without functional impairment. Present in approximately 33% of PLWH in the CHARTER study.
• Mild Neurocognitive Disorder (MND) — performance ≥1 SD below norms in ≥2 domains with mild functional impairment. Present in approximately 12% of PLWH.
• HIV-Associated Dementia (HAD) — performance ≥2 SD below norms in ≥2 domains with marked functional impairment. Now rare (2–5%) with effective ART but devastating when it occurs.

Cognitive Domain Profile

HAND characteristically affects domains associated with fronto-striatal and subcortical circuitry: processing speed, executive function, learning efficiency (with relatively preserved recognition memory compared to encoding deficits), motor function, and attention/working memory. Language and visuospatial skills are relatively preserved unless disease is advanced. This subcortical profile contrasts with Alzheimer's disease, which produces prominent amnesia and cortical deficits early in its course.

Controversies in HAND Diagnosis

The ANI category has been criticized by some researchers as potentially over-diagnosing neurocognitive impairment. Because ANI is defined statistically (performance below normative expectations without functional impairment), the base rate of false positives using a 1 SD cutoff in 2 of 7+ cognitive domains is not negligible. Critics argue that ANI may capture normal variation rather than disease, particularly when normative data are poorly matched for demographic factors. However, longitudinal data from CHARTER and other cohorts suggest that ANI does carry prognostic significance — individuals with ANI are more likely to progress to symptomatic impairment compared to neurocognitively normal PLWH, supporting its clinical utility as a risk marker.

CSF Escape and Persistent Inflammation

A subset of virally suppressed PLWH demonstrates detectable HIV RNA in CSF despite undetectable plasma viral load — a phenomenon termed CSF viral escape — occurring in approximately 5–15% of treated individuals. CSF escape is associated with neuroinflammation, ongoing cognitive decline, and new or worsening neurological symptoms. Additionally, even in the absence of CSF escape, biomarkers of neuroinflammation (neopterin, CSF neurofilament light chain, soluble CD14, MCP-1) remain elevated in many PLWH, suggesting persistent CNS immune activation despite peripheral viral suppression.

Management

The cornerstone of HAND management is optimized ART, ideally including agents with high CNS penetration effectiveness (CPE score). The concept of CPE scoring (developed by Letendre et al.) ranks antiretrovirals by their estimated CNS penetration, with higher CPE regimens theoretically providing better viral control in the CNS. However, clinical trial data on the benefit of CPE-optimized regimens for HAND are mixed. Some observational studies suggest benefit, while others — including a randomized study by Ellis et al. (2014) — did not demonstrate significant cognitive improvement from CPE-optimized ART switches.

Pharmacological interventions for HAND beyond ART optimization have been largely disappointing. Trials of memantine, minocycline, selegiline, and lithium have not produced consistent cognitive benefits. Cognitive rehabilitation programs show modest benefits on specific domains, and physical exercise interventions have emerging evidence for neuroprotective effects in PLWH, paralleling findings in aging and Alzheimer's disease research.

While ART has transformed HIV from a fatal illness to a manageable chronic condition, several antiretroviral agents produce neuropsychiatric side effects that can mimic or worsen primary psychiatric disorders. Awareness of these effects is essential for accurate diagnosis and collaborative management between HIV and mental health providers.

Efavirenz (EFV)

Efavirenz, a first-generation NNRTI, is the most extensively studied ART agent for neuropsychiatric toxicity. CNS side effects including vivid dreams, insomnia, dizziness, impaired concentration, depersonalization, and mood disturbance affect approximately 40–60% of patients in the first 2–4 weeks of treatment, with the majority experiencing spontaneous resolution within 4–6 weeks. However, approximately 10–20% report persistent symptoms. Critically, efavirenz has been associated with increased depression and suicidality in some studies. A secondary analysis of the STAR*D-equivalent AIDS Clinical Trials Group (ACTG) studies, and data from the Strategic Timing of Antiretroviral Treatment (START) trial, suggested a small but significant increase in depression risk with efavirenz-containing regimens compared to alternatives. Due to these neuropsychiatric concerns and the availability of better-tolerated alternatives (e.g., dolutegravir, bictegravir), efavirenz has been replaced as a preferred first-line agent in most high-income country guidelines, though it remains widely used in resource-limited settings.

The mechanism of efavirenz neuropsychiatric effects involves partial agonism at serotonin 5-HT_2A and 5-HT_2C receptors, inhibition of mitochondrial complex I in neurons, and a metabolite (8-hydroxy-efavirenz) with possible neurotoxic properties. The CYP2B6 slow metabolizer genotype (CYP2B6 516G→T, more common in people of African descent) results in higher efavirenz plasma levels and is associated with a significantly increased risk of neuropsychiatric side effects.

Integrase Strand Transfer Inhibitors (INSTIs)

INSTIs — dolutegravir (DTG), bictegravir (BIC), raltegravir (RAL), cabotegravir (CAB), and elvitegravir (EVG) — are now the backbone of preferred first-line ART regimens globally. While generally well-tolerated, neuropsychiatric side effects have emerged as a recognized concern, particularly with dolutegravir. Reported effects include insomnia (8–15%), headache, anxiety, depression, and in rare cases suicidal ideation. In clinical trials and observational cohorts, INSTI discontinuation rates due to neuropsychiatric adverse events range from approximately 1–6%, with higher rates in older patients and women.

A large observational study by Elzi et al. (2017) from the Swiss HIV Cohort Study reported neuropsychiatric discontinuation rates of 5.6% for dolutegravir, compared to 2.2% for raltegravir and lower rates for bictegravir. The ADVANCE trial, conducted in South Africa, found comparable rates of neuropsychiatric complaints between dolutegravir and efavirenz arms, challenging the perception that INSTIs are uniformly better tolerated. The mechanism of INSTI neuropsychiatric effects is not well established; proposed mechanisms include effects on magnesium-dependent enzymes in the CNS and disruption of hypothalamic calcium signaling.

Other Agents

Zidovudine (AZT) can cause fatigue, headache, and insomnia, particularly at higher doses. Some protease inhibitors are associated with fatigue and mood changes. Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) have minimal direct CNS effects but can cause weight gain (particularly TAF), which may secondarily affect mood and self-image.

Clinical Implications

When PLWH present with new or worsening psychiatric symptoms, temporal correlation with ART initiation or switch should always be assessed. In many cases, psychiatric symptoms resolve with ART modification, obviating the need for psychotropic medications. Collaborative management between HIV physicians and psychiatrists is essential to balance viral suppression with neuropsychiatric tolerability.

Substance use disorders (SUDs) are intertwined with the HIV epidemic at every level — transmission risk, disease progression, treatment adherence, and psychiatric comorbidity. The syndemic concept, articulated by Singer and others, describes the mutually reinforcing interaction of HIV, SUDs, mental illness, and social adversity as co-occurring, synergistic epidemics.

Prevalence and Impact

Injection drug use remains a major route of HIV transmission globally, accounting for approximately 10% of new infections worldwide and a substantially higher proportion in Eastern Europe and Central Asia. Beyond injection, methamphetamine use, crack cocaine use, and hazardous alcohol consumption are independently associated with increased HIV acquisition risk, accelerated disease progression, and poor treatment outcomes. Among PLWH in the U.S., estimates suggest 40–60% have a current or lifetime SUD, compared to approximately 15% in the general adult population.

Alcohol use disorder deserves particular attention: even moderate alcohol consumption is associated with reduced ART adherence and has direct hepatotoxic effects that interact with ART-related liver toxicity. A study by Hendershot et al. (2009) found that alcohol use was associated with a 50–60% increase in the odds of ART non-adherence.

Pharmacological Treatment Considerations

Medication-assisted treatment for opioid use disorder (OUD) — including methadone, buprenorphine/naloxone, and extended-release naltrexone — is critically important for PLWH with OUD. Key interaction considerations include:

• Methadone levels are significantly reduced by efavirenz (CYP3A4 induction), potentially precipitating opioid withdrawal. Dose adjustments of 25–50% may be necessary.
• Ritonavir and cobicistat can increase or decrease methadone levels unpredictably depending on the balance of CYP3A4 inhibition and CYP induction.
• Buprenorphine has fewer ART interactions and is increasingly favored in HIV clinic settings. It can be safely co-prescribed with INSTIs, NNRTIs (except potentially with certain newer agents requiring monitoring), and most PIs.

For alcohol use disorder, naltrexone and acamprosate have minimal ART interactions and can be used safely. Disulfiram should be used cautiously due to potential hepatotoxicity in patients with HIV-HCV co-infection.

Integrated Treatment

Integrated models co-locating SUD treatment within HIV primary care settings have demonstrated superior outcomes compared to parallel or sequential referral models. The BHIVES (Buprenorphine HIV Evaluation and Support) collaborative, a SAMHSA-funded multisite project, demonstrated the feasibility and effectiveness of office-based buprenorphine treatment integrated into HIV clinic settings.

The co-occurrence of HIV, psychiatric disorders, and substance use disorders demands integrated service delivery models. Fragmented care — where HIV treatment, mental health, and SUD services exist in separate systems with separate providers, records, and funding streams — is associated with treatment gaps, poor adherence, and worse outcomes across all conditions.

Collaborative Care

The collaborative care model (CoCM), originally developed by Katon and Unützer for depression in primary care, has been adapted for HIV clinic settings with strong evidence. The HITIDES (HIV Translating Initiatives for Depression into Effective Solutions) trial demonstrated that a collaborative care intervention — integrating a depression care manager, supervising psychiatrist, and measurement-based treatment into HIV primary care — produced significantly greater depression improvement (approximately 10-point PHQ-9 reduction) and ART adherence compared to enhanced usual care over 12 months.

Medical Home and One-Stop-Shop Models

The Ryan White HIV/AIDS Program in the United States funds comprehensive HIV care including mental health services, case management, and substance use treatment. HIV clinics operating under medical home principles — with co-located psychiatric, psychological, and social work services — have demonstrated improved viral suppression rates, reduced emergency department utilization, and better mental health outcomes. The Health Resources and Services Administration (HRSA) HIV/AIDS Bureau performance measures specifically track mental health screening and referral rates.

Task-Shifting in Resource-Limited Settings

In sub-Saharan Africa and other resource-limited settings where psychiatric specialists are extremely scarce (in some countries, fewer than 1 psychiatrist per million population), task-shifting models that train non-specialist health workers to deliver evidence-based mental health interventions have demonstrated efficacy. The SHARP (Strengthening HIV and AIDS Response Partnerships) trial and multiple studies from Uganda and South Africa have shown that lay counselors and nurses can effectively deliver manualized psychological interventions (particularly interpersonal therapy and problem-solving therapy) for depression in PLWH, with outcomes comparable to specialist-delivered therapy.

Telemental Health

Telehealth delivery of psychiatric services to PLWH has expanded dramatically since the COVID-19 pandemic. Multiple studies demonstrate equivalent outcomes for telepsychiatry and telehealth-delivered psychotherapy compared to in-person modalities for depression and anxiety in PLWH. Telemental health is particularly valuable for PLWH in rural areas, those with mobility limitations, and those for whom clinic attendance poses stigma-related barriers.

The intersection of HIV and mental health varies significantly across populations, requiring culturally and contextually informed approaches.

Women Living with HIV

Women living with HIV experience depression at rates even higher than men — estimated at 30–55% depending on the population and measurement method. Gender-based violence, reproductive coercion, economic dependence, caregiving burden, and perinatal depression all contribute. Perinatal depression in women with HIV is particularly consequential because it threatens ART adherence during pregnancy and postpartum, directly affecting prevention of mother-to-child transmission (PMTCT). The safety profile of psychotropic medications in pregnancy requires careful consideration: sertraline and fluoxetine are generally considered acceptable based on reproductive safety data, while paroxetine carries a small increased risk of cardiac malformations and is typically avoided.

Aging with HIV

As ART has extended life expectancy, over 50% of PLWH in high-income countries are now over age 50, and this proportion is rising. Aging PLWH face a convergence of HIV-related neuroinflammation, age-related neurodegenerative processes, cardiovascular disease, and polypharmacy. Depression prevalence in older PLWH is estimated at 25–40%. Neurocognitive concerns are amplified: the interaction between HIV neuropathology and age-related cognitive decline raises concerns about accelerated Alzheimer's-like pathology, though direct evidence for increased Alzheimer's disease risk in PLWH remains inconclusive. Older PLWH also experience increased social isolation, bereavement-related grief (particularly long-term survivors who lost entire social networks in the early epidemic), and age-related stigma overlapping with HIV stigma.

Men Who Have Sex with Men (MSM), Transgender Individuals, and Other Key Populations

MSM continue to be disproportionately affected by HIV in most countries and experience elevated rates of depression, anxiety, SUDs, and suicidality related to minority stress, homophobia, and intersectional stigma. Transgender women have among the highest HIV prevalence of any population globally (estimated at 19% in a meta-analysis by Baral et al., 2013) and face compounded stigma, violence, and mental health burden. Mental health care for these populations must be affirming, trauma-informed, and cognizant of the specific psychosocial stressors they face.

Understanding what predicts mental health outcomes in PLWH helps clinicians identify those at highest risk and allocate resources accordingly.

Prognostic Factors for Depression Outcomes

Factors associated with poorer depression treatment response in PLWH include:

• Co-occurring substance use disorders — the strongest and most consistent predictor of treatment non-response and relapse
• Higher baseline depression severity — consistent with general MDD literature
• Advanced immunosuppression (nadir CD4 < 200) — reflecting greater CNS disease burden
• Higher internalized stigma — independently predicts worse depression trajectory
• History of childhood trauma — associated with HPA axis dysregulation and treatment resistance
• Social isolation and lack of social support
• Untreated pain — chronic pain affects an estimated 30–55% of PLWH and bidirectionally exacerbates depression

Conversely, factors associated with better outcomes include: stable housing, employment, strong social support, engagement in HIV care, viral suppression, and access to integrated mental health services.

Research Frontiers

Several active research areas hold promise for improving psychiatric care in PLWH:

• Neuroinflammation-targeted therapies — given the central role of neuroinflammation in both depression and HAND, anti-inflammatory interventions (e.g., minocycline, statins, celecoxib as adjunctive antidepressant therapy) are under investigation, though results have been inconclusive to date.
• Gut-brain axis — HIV profoundly disrupts the gut microbiome and intestinal barrier integrity, leading to microbial translocation and systemic immune activation. The emerging understanding of microbiome-brain communication suggests this may be a relevant pathway linking HIV to depression and neurocognitive impairment.
• Long-acting injectable ART and mental health — the advent of long-acting cabotegravir/rilpivirine injections eliminates the daily adherence burden that is so heavily influenced by depression and cognitive impairment. Research is needed on whether this approach improves psychiatric outcomes or if the adherence barrier simply shifts to clinic visit attendance.
• Psychedelic-assisted therapy — early-phase research is exploring psilocybin and MDMA-assisted therapy for treatment-resistant depression and PTSD in PLWH, building on promising results in non-HIV populations. These remain experimental.
• Digital mental health interventions — smartphone-based interventions for depression self-management, adherence support, and relapse prevention are being tested in PLWH across diverse settings.

Limitations of Evidence

The evidence base for psychiatric treatment in PLWH, while growing, has notable limitations: (1) most antidepressant RCTs in PLWH are small, with limited statistical power; (2) racial and ethnic minority populations, women, and individuals in low- and middle-income countries are underrepresented in treatment trials; (3) there is limited evidence on long-term psychiatric outcomes beyond 12–24 months in most studies; (4) trials rarely address the complex polypharmacy reality of PLWH with multiple comorbidities; and (5) the heterogeneity of HAND diagnostic approaches limits the comparability of neurocognitive outcome studies.